| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
2
|
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
|
N Engl J Med
|
2012
|
35.24
|
|
3
|
Nivolumab plus ipilimumab in advanced melanoma.
|
N Engl J Med
|
2013
|
17.53
|
|
4
|
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
|
J Clin Oncol
|
2010
|
17.13
|
|
5
|
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
|
J Exp Med
|
2009
|
4.68
|
|
6
|
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
|
Cancer Res
|
2011
|
3.81
|
|
7
|
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
|
Curr Opin Immunol
|
2006
|
3.12
|
|
8
|
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
|
Cancer Immunol Res
|
2013
|
2.76
|
|
9
|
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
|
Int Immunol
|
2007
|
2.67
|
|
10
|
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
|
Ann N Y Acad Sci
|
2013
|
2.03
|
|
11
|
BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
|
Clin Cancer Res
|
2012
|
1.42
|
|
12
|
Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
|
Crit Care
|
2013
|
1.37
|
|
13
|
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
|
J Immunother
|
2010
|
1.37
|
|
14
|
Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3.
|
J Immunol
|
2011
|
1.28
|
|
15
|
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
|
J Clin Invest
|
2015
|
1.22
|
|
16
|
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
|
PLoS One
|
2013
|
1.12
|
|
17
|
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice.
|
J Immunol
|
2012
|
1.07
|
|
18
|
B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
|
J Immunol
|
2012
|
1.02
|
|
19
|
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
|
J Transl Med
|
2012
|
0.80
|
|
20
|
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.
|
Oncoimmunology
|
2012
|
0.78
|
|
21
|
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
|
Cell Res
|
2015
|
0.77
|
|
22
|
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
|
PLoS One
|
2016
|
0.75
|
|
23
|
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
|
Cancer Cell
|
2015
|
0.75
|